Search & Analyze

Alembic Pharmaceuticals Ltd.

HealthcarePharmaceuticals & Drugs

www.alembicpharmaceuticals.com BSE: 533573NSE: APLLTD

₹823.15BSE0.45%

16 Sep, 4:01 PM

₹823.15

₹16.20K Cr

23.37

2.77

12.35%

₹838.60

₹817.25

₹998.00

₹635.30

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Alembic Pharmaceuticals Ltd. APLLTD	823.15	23.37	16,204.66	1.46	172.36	12.19%	2,149.77	25.66%	11.74

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,516.97	1,561.73	1,647.98	1,692.74	1,769.64	1,710.72	1,910.15	1,876.31	1,847.72	2,149.77
Expenses	1,256.92	1,324.90	1,408.71	1,432.52	1,497.72	1,429.38	1,594.46	1,582.81	1,619.80	1,817.91
	260.05	236.83	239.27	260.22	271.92	281.34	315.69	293.50	227.92	331.86
	17.14%	15.16%	14.52%	15.37%	15.37%	16.45%	16.53%	15.64%	12.34%	15.44%
	3.60	2.10	29.61	9.51	14.19	6.50	6.91	-26.73	0.74	14.93
Interest	10.94	13.18	18.81	22.26	24.52	23.52	24.23	23.31	22.56	27.61
	69.48	69.04	70.51	70.04	68.99	73.77	76.07	80.12	88.59	97.71
	182.84	157.03	180.42	177.78	191.94	190.10	223.72	161.50	118.62	221.86
	2.53%	14.32%	15.12%	22.54%	18.40%	19.18%	17.88%	18.30%	-69.90%	22.31%
	178.21	134.71	153.40	138.42	156.89	154.38	184.71	132.97	202.70	173.07
	9.07	6.85	7.80	7.04	7.98	7.85	9.40	6.77	10.31	8.81

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	5,305.78	5,652.62	13,449.71	13,412.85	14,252.37
	5,305.78	5,652.62	6,228.63	6,672.08	7,344.90
EXPENDITURE :
Increase/Decrease in Stock	-43.18	78.64	-142.84	-289.77	-271.81
Raw Material Consumed	1,489.61	1,630.18	1,857.92	2,083.13	2,256.26
Power & Fuel Cost	120.84	151.54	173.37	179.69	177.50
Employee Cost	1,133.00	1,169.13	1,446.29	1,562.34	1,731.93
Other Manufacturing Expenses	379.15	409.37	387.71	440.63	507.61
General and Administration Expenses	413.90	492.64	525.84	576.39	682.47
Selling and Distribution Expenses	890.38	952.30	996.88	1,064.86	1,083.11
Miscellaneous Expenses	47.94	60.76	50.83	51.89	59.83
	4,431.64	4,944.56	5,296.00	5,669.16	6,226.90
Operating Profit (Excl OI)	874.14	708.06	932.63	1,002.92	1,118.00
	50.49	3.04	29.04	47.87	54.88
	924.63	711.10	961.67	1,050.79	1,172.88
Interest	17.73	50.17	56.19	78.77	93.63
PBDT	906.90	660.93	905.48	972.02	1,079.25
	286.78	275.43	272.67	278.58	318.55
Profit Before Taxation & Exceptional Items	620.12	385.50	632.81	693.44	760.70
Exceptional Income / Expenses				12.87	-66.99
	625.40	354.59	631.83	707.18	693.95
Provision for Tax	104.46	12.60	16.01	125.17	23.12
	520.94	341.99	615.82	582.01	670.83
Extra items			0.00	0.00	0.00
Minority Interest				1.41	3.94
Consolidated Net Profit	520.94	341.99	615.82	583.42	674.77
Profit Balance B/F	2,384.94	2,554.39	3,568.44	4,027.01	4,394.22
Appropriations	2,905.88	2,896.38	4,184.26	4,610.43	5,068.99
Equity Dividend %	500.00%	400.00%	550.00%	550.00%	600.00%
	26.50	17.40	31.33	29.68	34.33
Adjusted EPS	26.50	17.40	31.33	29.68	34.33

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	39.31	39.31	39.31	39.31	39.31
Total Reserves	5,198.23	4,331.16	4,778.89	5,151.63	5,635.50
Reserve excluding Revaluation Reserve	5,198.23	4,331.16	4,778.89	5,151.63	5,635.50
Revaluation reserve	0.00	0.00		0.00
	5,237.54	4,370.47	4,818.20	5,190.94	5,674.81
Minority Interest				-1.42	-5.83
Unsecured Loans					121.92
Deferred Tax Assets / Liabilities	-5.89	-123.01	-169.64	-166.03	-269.61
Other Long Term Liabilities	72.14	69.23	62.88	46.77	224.94
Long Term Provisions	95.82	106.20	109.51	124.31	152.91
Total Non-Current Liabilities	162.07	52.42	2.75	5.05	230.16
Trade Payables	706.39	679.81	735.64	879.89	835.08
Other Current Liabilities	516.51	251.19	223.66	232.10	393.96
Short Term Borrowings	430.00	635.87	430.45	1,195.57	1,218.61
Short Term Provisions	177.69	73.93	130.53	206.71	239.22
Total Current Liabilities	1,830.59	1,640.80	1,520.28	2,514.27	2,686.87
Total Liabilities	7,230.20	6,063.69	6,341.23	7,708.84	8,586.01
Gross Block	2,840.33	3,467.50	3,875.21	4,117.32	4,896.99
Less: Accumulated Depreciation	1,042.48	1,069.05	1,328.50	1,593.79	1,816.32
Net Block	1,797.85	2,398.45	2,546.71	2,523.53	3,080.67
Capital Work in Progress	2,205.80	601.28	524.36	837.23	633.70
Non Current Investments	118.40	96.33	93.02	127.21	140.88
Long Term Investment	118.40	96.33	93.02	127.21	140.88
Long Term Loans & Advances	34.88	53.74	33.30	31.15	15.43
Other Non Current Assets	0.00	0.00		0.00
Total Non-Current Assets	4,255.37	3,149.80	3,197.39	3,519.12	3,920.38
Inventories	1,609.70	1,475.27	1,643.54	2,288.14	2,510.65
Sundry Debtors	807.13	1,046.41	1,024.84	1,399.79	1,466.30
Cash and Bank	69.43	82.27	126.57	90.09	202.70
Other Current Assets	51.65	55.32	59.86	69.17	80.76
Short Term Loans and Advances	436.92	254.62	289.03	342.53	375.22
Total Current Assets	2,974.83	2,913.89	3,143.84	4,189.72	4,635.63
Net Current Assets (Including Current Investments)	1,144.24	1,273.09	1,623.56	1,675.45	1,948.76
Total Assets	7,230.20	6,063.69	6,341.23	7,708.84	8,586.01
Contingent Liabilities	62.87	109.23	54.61	68.89	160.39
Total Debt	629.99	635.87	430.45	1,195.57	1,360.85
	266.47	222.36	245.14	264.10	288.72
Adjusted Book Value	266.47	222.36	245.14	264.10	288.72

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	625.39	354.59	631.83	707.18	693.95
Adjustment	417.75	487.61	286.87	373.53	449.31
Changes In working Capital	-367.36	-57.56	-95.65	-921.36	-256.82
Cash Flow after changes in Working Capital	675.78	784.64	823.05	159.35	886.44
Cash Flow from Operating Activities	552.35	723.94	803.20	87.97	782.73
Cash Flow from Investing Activities	-371.97	-447.59	-320.61	-568.41	-506.06
Cash Flow from Financing Activitie	-217.35	-261.96	-437.86	443.71	-163.78
Net Cash Inflow / Outflow	-36.97	14.39	44.73	-36.73	112.89
Opening Cash & Cash Equivalents	98.06	61.09	75.48	120.21	83.48
Closing Cash & Cash Equivalent	61.09	75.48	120.21	83.48	196.37

Ratios

Valuation

23.37

2.77

14.10

2.08

35.28

297.45

Profitability

12.35

11.74

8.23

7.84

4.71

Leverage & Liquidity

0.24

1.73

8.41

Returns

1.46

1.75

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	69.61	69.61	69.61	69.67	69.67	69.74	69.74	69.74	69.87
	19.79	19.99	20.23	20.37	20.42	20.35	20.41	20.43	20.12
	10.60	10.40	10.16	9.96	9.90	9.92	9.86	9.83	10.01
	30.39	30.39	30.39	30.33	30.33	30.26	30.26	30.26	30.13
No. of Shareholders	74,829	91,429	93,944	91,336	89,013	89,969	87,000	86,432	86,796

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-24	Board Meeting	Quarterly Results
2026-07-10	AGM
2026-05-15	Ex Dividend	Rs.12.0000 per share(600%)Final Dividend	2026-07-29	2026-07-29

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-06-19	Nirayu Pvt Ltd	Market	Buy	3,278
2026-06-18	Nirayu Pvt Ltd	Market	Buy	24,832
2026-06-12	Nirayu Pvt Ltd	Market	Buy	75,000
2026-06-03	Nirayu Pvt Ltd	Market	Buy	20,000
2026-05-28	Nirayu Pvt Ltd	Market	Buy	78,000

Sector Overview

HealthcarePharmaceuticals & Drugs

Alembic Pharmaceuticals Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

11 members across the board and senior leadership

Chirayu Amin

Chairman

₹14.22 Cr

Mar '26

Pranav Amin

Managing Director

₹19.13 Cr

Mar '26

Shaunak Amin

Managing Director

₹19.13 Cr

Mar '26

Ashok Kumar Barat

Non Executive Independent Director

₹29.00 Cr

Mar '26

R K Baheti

Executive Director - Finance & CFO

₹8.28 Cr

Mar '25

Jai Diwanji

Non Executive Independent Director

₹28.40 Cr

Mar '26

Manish Kejriwal

Non Executive Independent Director

₹25.10 Cr

Mar '26

Geeta Goradia

Non Executive Independent Director

₹27.80 Cr

Mar '26

Sujit Jaysukh Bhayani

Independent Director

—

Manisha Saraf

Company Secretary & Compliance Officer

—

Chirag Shukla

Company Secretary & Compliance Officer

—

APLLTD Latest News

News

10 of 10 articles

EQUITY11 Sept 2026 · 14:52

Alembic Pharmaceuticals informs about disclosure

COMPANY11 Sept 2026 · 12:50

USFDA completes inspection at Alembic Pharmaceuticals’ Bioequivalence Facility in Vadodara

The inspection was conducted at the company’s Bioequivalence Facility located in Vadodara and concluded with no Form 483 observations

COMPANY8 Sept 2026 · 10:27

Alembic Pharmaceuticals incorporates subsidiary in Dubai

The new entity has been incorporated to explore new business opportunities and to promote, sale and distribute pharmaceutical product(s) of the company

EQUITY5 Aug 2026 · 09:27

Alembic Pharmaceuticals shines on reporting 12% rise in Q1 consolidated net profit

Consolidated total income of the company increased by 26.06% to Rs 2,164.70 crore in Q1FY27

COMPANY4 Aug 2026 · 16:00

Alembic Pharmaceuticals reports 12% rise in Q1 consolidated net profit

Consolidated total income of the company increased by 26.06% to Rs 2,164.70 crore in Q1FY27

EQUITY28 Jul 2026 · 15:19

Alembic Pharma moves up on getting USFDA’s final approval for Prucalopride Tablets

Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults

COMPANY28 Jul 2026 · 15:12

Alembic Pharma gets USFDA’s final approval for Prucalopride Tablets

Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults

EQUITY20 Jul 2026 · 11:08

Alembic Pharmaceuticals moves up as its partner NATCO gets USFDA’s tentative nod for Olaparib Tablets

The company will distribute the product in the U.S., and its partner NATCO will manufacture Olaparib Tablets, 100 mg and 150 mg

COMPANY20 Jul 2026 · 09:44

Alembic Pharmaceuticals' partner NATCO gets USFDA’s tentative nod for Olaparib Tablets

The company will distribute the product in the U.S., and its partner NATCO will manufacture Olaparib Tablets, 100 mg and 150 mg

COMPANY29 Jun 2026 · 14:44

Alembic Pharmaceuticals gets USFDA’s final approval for Dapsone Gel

Alembic has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA

APLLTD

₹823.15

+0.45%